[Form 4] Cytokinetics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics Inc. (CYTK), reported transactions dated 09/09/2025 under a Rule 10b5-1 plan. He exercised 2,000 non‑qualified stock options at a $10.60 exercise price and acquired 2,000 shares, and concurrently sold 2,000 shares at $51.29. After these transactions he beneficially owns 140,610 shares.

Positive

• Exercise of options converted 2,000 options into common stock at a $10.60 exercise price, securing equity rather than forfeiture
• Transactions executed under a 10b5-1 plan, indicating pre-planned and rule-compliant trading

Negative

• Sale of 2,000 shares reduced holdings by that amount, lowering beneficial ownership from 142,610 to 140,610
• No additional context on purpose or size-relative impact to overall holdings beyond the reported totals

Insights

Financial Analyst

TL;DR: Insider exercised options at $10.60 and sold an equal number of shares at $51.29, leaving total beneficial ownership of 140,610 shares.

The filing shows a routine option exercise and sale under a 10b5-1 plan on 09/09/2025. Exercising 2,000 options previously granted (exercise price $10.60) converted derivative instruments into common stock; the simultaneous sale of 2,000 shares at $51.29 realized gains for the reporting person. The net beneficial holding after the transactions is 140,610 shares.

Corporate Governance Expert

TL;DR: Transactions were executed pursuant to an affirmative defense 10b5-1 plan and were signed by an attorney‑in‑fact.

The Form 4 is marked to indicate the trades were made under a written 10b5-1 plan, which provides an affirmative defense to insider trading claims when properly adopted. The signature block shows the form was filed by an attorney‑in‑fact on 09/10/2025, consistent with authorized filing practices. No amendments or unusual disclosures are present.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		M		2,000	A	$10.6	142,610	D
Common Stock	09/09/2025		S		2,000	D	$51.29	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	09/09/2025		M			2,000	03/28/2017	02/28/2027	Common Stock	2,000	$0	7,105	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did CYTK insider Dr. Malik F. Ibraham report on 09/09/2025?

He exercised 2,000 non‑qualified stock options at a $10.60 exercise price (acquiring 2,000 shares) and sold 2,000 shares at $51.29.

How many CYTK shares does Dr. Malik own after the reported transactions?

The Form 4 reports he beneficially owns 140,610 shares following the transactions.

Were the transactions conducted under a Rule 10b5-1 plan?

Yes. The filing is marked to indicate the transactions were made pursuant to a 10b5-1 written plan.

What option grant details are disclosed in the Form 4?

The exercised non‑qualified stock option had an exercise price of $10.60, was exercisable from 03/28/2017 and expires 02/28/2027, covering 2,000 underlying shares.

Who signed the Form 4 filing for the reporting person?

The form was signed by John O. Faurescu, attorney‑in‑fact for Dr. Malik on 09/10/2025.